Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of dupilumab in patients with moderate to severe uncontrolled asthma
2013-000856-16Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Dupilumab dose-ranging regimens with Placebo (2 arms). Primary endpoint: Change from baseline in FEV1. Started May 2013; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on 2013-000856-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000856-16.